Uterine Smooth Muscle Tumors of Uncertain Malignant Potential (STUMP): A clinicopathologic analysis of 16 cases

American Journal of Surgical Pathology

Volumn 33, Issue 7, 2009, Pages 992-1005

  Philip, P C ^a   Cheung, Annie N Y ^a   Clement, Philip B ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Atypical leiomyoma; Gonadotropin releasing hormone analog; Leiomyosarcoma; p16; p53; Smooth muscle tumor of low malignant potential; Uterine leiomyoma; Uterine smooth muscle tumor of uncertain malignant potential (STUMP)

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P16; PROTEIN P53;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOSARCOMA; MYOMETRIUM; OUTCOME ASSESSMENT; SMOOTH MUSCLE TUMOR OF UNCERTAIN MALIGNANT POTENTIAL; SURVIVAL RATE; TUMOR CLASSIFICATION; TUMOR DIAGNOSIS; TUMOR RECURRENCE; UTERUS TUMOR;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HISTORY, 16TH CENTURY; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SMOOTH MUSCLE TUMOR; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES; UTERINE NEOPLASMS;

EID: 67649497499     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181a02d1c     Document Type: Article

References (70)

1. Akhan SE, Yavuz E, Tecer A, et al. The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study. Gynecol Oncol. 2005; 99:36-42.
2. Amada S, Nakano H, Tsuneyoshi M. Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins. Int J Gynecol Pathol. 1995;14:134-142.
3. Amant F, Moerman P, Vergote I. Report of an unusual problematic uterine smooth muscle neoplasm, emphasizing the prognostic importance of coagulative tumor cell necrosis. Int J Gynecol Cancer. 2005;15:1210-1212.
4. Atkins KA, Arronte N, Darus CJ, et al. The use of p16 in enhancing the histologic classification of uterine smooth muscle tumors. Am J Surg Pathol. 2008;32:98-102.
5. Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol. 1994;18:535-558.
6. Berretta R, Rolla M, Merisio C, et al. Uterine smooth muscle tumor of uncertain malignant potential: a three-case report. Int J Gynecol Cancer. 2008;18:1121-1126.
7. Blom R, Guerrieri C, Stal O, et al. Leiomyosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases. Gynecol Oncol. 1998;68:54-61.
8. Bodner-Adler B, Bodner K, Czerwenka K, et al. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. Gynecol Oncol. 2005;96:62-66.
9. Bodner K, Bodner-Adler B, Kimberger O, et al. Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors. Fertil Steril. 2004;81:1062-1066.
10. Chen L, Yang B. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. Int J Gynecol Pathol. 2008;27:326-332.
11. Clement PB. The pathology of uterine smooth muscle tumors and mixed endometrial stromal-smooth muscle tumors: a selective review with emphasis on recent advances. Int J Gynecol Pathol. 2000;19:39-55.
12. Clement PB, Young RH. Atlas of Gynecologic Surgical Pathology. Philadelphia: Saunders; 2007:200.
13. Clement PB, Young RH, Scully RE. Nontrophoblastic pathology of the female genital tract and peritoneum associated with pregnancy. Semin Diagn Pathol. 1989;6:372-406.
14. Cohen D, Mazur MT, Jozefczyk MA, et al. Hyalinization and cellular changes in uterine leiomyomata after gonadotropin releasing hormone agonist therapy. J Reprod Med. 1994;39:377-380.
15. Colgan TJ, Pendergast S, LeBlanc M. The histopathology of uterine leiomyomas following treatment with gonadotropin-releasing hormone analogues. Hum Pathol. 1993;24:1073-1077.
16. Crow J, Gardner RL, McSweeney G, et al. Morphological changes in uterine leiomyomas treated by GnRH agonist goserelin. Int J Gynecol Pathol. 1995;14:235-242.
17. de Vos S, Wilczynski SP, Fleischhacker M, et al. p53 alterations in uterine leiomyosarcomas versus leiomyomas. Gynecol Oncol. 1994; 54:205-208.
18. Donhuijsen K, Schmidt U, Hirche H, et al. Changes in mitotic rate and cell cycle fractions caused by delayed fixation. Hum Pathol. 1990;21:709-714.
19. Downes KA, Hart WR. Bizarre leiomyomas of the uterus: a comprehensive pathologic study of 24 cases with long-term followup. Am J Surg Pathol. 1997;21:1261-1270.
20. Esposito NN, Hunt JL, Bakker A, et al. Analysis of allelic loss as an adjuvant tool in evaluation of malignancy in uterine smooth muscle tumors. Am J Surg Pathol. 2006;30:97-103.
21. Gao HG, LiVolsi VA, Zhang PJ. Utility of trichrome and reticulum stains in characterizing necroses in uterine smooth muscle tumors [Abstract]. Mod Pathol. 2007;20:198A.
22. Gutmann JN, Thornton KL, Diamond MP, et al. Evaluation of leuprolide acetate treatment on histopathology of uterine myomata. Fertil Steril. 1994;61:622-626.
23. Hall KL, Teneriello MG, Taylor RR, et al. Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas. Gynecol Oncol. 1997;65:330-335.
24. Hart WR. Problematic uterine smooth muscle neoplasms [Letter]. Am J Surg Pathol. 1997;21:252-255.
25. Hart WR, Billman JK Jr. A reassessment of uterine neoplasms originally diagnosed as leiomyosarcomas. Cancer. 1978;41:1902-1910.
26. Hendrickson MR, Kempson RL. The uterine corpus. In: Sternberg SS, ed. Diagnostic Surgical Pathology. New York: Raven Press; 1989.
27. Hendrickson MR, Kempson RL. A diagnostic approach to smooth muscle tumours of the uterus. Curr Diagn Pathol. 2000;6:21-30.
28. Hendrickson MR, Longacre TA, Kempson RL. The uterine corpus. In: Stacey EMills, ed. Sternberg's Diagnostic Surgical Pathology. Philadelphia: Lippincott Williams & Wilkins; 2004.
29. Hitti IF, Glasberg SS, McKenzie C, et al. Uterine leiomyosarcoma with massive necrosis diagnosed during gonadotropin-releasing hormone analog therapy for presumed uterine fibroid. Fertil Steril. 1991;56:778-780.
30. Huang SE, Huang SC, Lee WY, et al. Pseudo-Meigs' syndrome caused by uterine smooth muscle tumor of uncertain malignant potential with low vascular endothelial growth factor expression. Int J Gynecol Cancer. 2007;18:851-853.
31. Ip PP, Lam KW, Cheung CL, et al. Tranexamic acid-associated necrosis and intralesional thrombosis of uterine leiomyomas: a clinicopathologic study of 147 cases emphasizing the importance of drug-induced necrosis and early infarcts in leiomyomas. Am J Surg Pathol. 2007;31:1215-1224.
32. Jeffers MD, Farquharson MA, Richmond JA, et al. p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus. J Pathol. 1995;177:65-70.
33. Kalir T, Goldstein M, Dottino P, et al. Morphometric and electronmicroscopic analyses of the effects of gonadotropin-releasing hormone agonists on uterine leiomyomas. Arch Pathol Lab Med. 1998;122:442-446.
34. Kawaguchi K, Fujii S, Konishi I, et al. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol. 1989;160:637-641.
35. Kempson RL. Sarcomas and related neoplasms. In: Norris HJ, Hertig AT, Abell MR, eds. The Uterus. Baltimore: Williams & Wilkins; 1973.
36. Kempson RL, Bari W. Uterine sarcomas. Classification, diagnosis, and prognosis. Hum Pathol. 1970;1:331-349.
37. Kumar V, Abbas A, Fausto N. Robbins and Cotran Pathologic Basis of Disease. Philadelphia: Elsevier Saunders; 2004.
38. Layfield LJ, Liu K, Dodge R, et al. Uterine smooth muscle tumors: utility of classification by proliferation, ploidy, and prognostic markers versus traditional histopathology. Arch Pathol Lab Med. 2000;124:221-227.
39. Lee WY, Tzeng CC, Chou CY. Uterine leiomyosarcomas coexistent with cellular and atypical leiomyomata in a young woman during the treatment with luteinizing hormone-releasing hormone agonist. Gynecol Oncol. 1994;52:74-79.
40. Longacre TA, Hendrickson MR, Kempson RL. Predicting clinical outcome for uterine smooth muscle neoplasms with a reasonable degree of certainty. Adv Anat Pathol. 1997;4:95-104.
41. Longacre TA, McKenney JK, Tazelaar HD, et al. Ovarian serous tumors of low malignant potential (borderline tumors): outcomebased study of 276 patients with long-term (> or =5-y) follow-up. Am J Surg Pathol. 2005;29:707-723.
42. Mayerhofer K, Lozanov P, Bodner K, et al. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS). Acta Obstet Gynecol Scand. 2004;83:1085-1088.
43. Mesia AF, Williams FS, Yan Z, et al. Aborted leiomyosarcoma after treatment with leuprolide acetate. Obstet Gynecol. 1998;92: 664-666.
44. Meyer WR, Mayer AR, Diamond MP, et al. Unsuspected leiomyo sarcoma: treatment with a gonadotropin-releasing hormone analogue. Obstet Gynecol. 1990;75:529-532.
45. Miettinen M, Fetsch JF. Evaluation of biological potential of smooth muscle tumours. Histopathology. 2006;48:97-105.
46. Mittal K, Demopoulos RI. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors. Hum Pathol. 2001;32:984-987.
47. Myles JL, Hart WR. Apoplectic leiomyomas of the uterus. A clinicopathologic study of five distinctive hemorrhagic leiomyomas associated with oral contraceptive usage. Am J Surg Pathol. 1985; 9:798-805.
48. Niemann TH, Raab SS, Lenel JC, et al. p53 protein overexpression in smooth muscle tumors of the uterus. Hum Pathol. 1995;26: 375-379.
49. Norris HJ, Hilliard GD, Irey NS. Hemorrhagic cellular leiomyomas (''apoplectic leiomyoma'') of the uterus associated with pregnancy and oral contraceptives. Int J Gynecol Pathol. 1988;7:212-224.
50. O'Connor DM, Norris HJ. Mitotically active leiomyomas of the uterus. Hum Pathol. 1990;21:223-227.
51. O'Neill CJ, McCluggage WG. p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol. 2006;13:8-15.
52. O'Neill CJ, McBride HA, Connolly LE, et al. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. Histopathology. 2007;50:851-858.
53. Perrone T, Dehner LP. Prognostically favorable ''mitotically active'' smooth-muscle tumors of the uterus. A clinicopathologic study of ten cases. Am J Surg Pathol. 1988;12:1-8.
54. Peters WA III, Howard DR, Andersen WA, et al. Uterine smoothmuscle tumors of uncertain malignant potential. Obstet Gynecol. 1994;83:1015-1020.
55. Pothuri B, Kehoe S, Wright T, et al. Clinical outcome of atypical uterine smooth muscle tumors [Abstract]. J Clin Oncol. 2006; 24:15028.
56. Prayson RA, Hart WR.Mitotically active leiomyomas of the uterus. Am J Surg Pathol. 1992;97:14-20.
57. Quade BJ, Pinto AP, Howard DR, et al. Frequent loss of heterozygosity for chromosome 10 in uterine leiomyosarcoma in contrast to leiomyoma. Am J Pathol. 1999;154:945-950.
58. Rein MS, Barbieri RL, Welch W, et al. The concentrations of collagen-associated amino acids are higher in GnRH agonist-treated uterine myomas. Obstet Gynecol. 1993;82:901-905.
59. Scurry J, Kerdemelidis P, Fortune D. Small atypical leiomyomas: report of two cases. Pathology. 2001;33:319-321.
60. Shapiro A, Ferenczy A, Turcotte R, et al. Uterine smooth-muscle tumor of uncertain malignant potential metastasizing to the humerus as a high-grade leiomyosarcoma. Gynecol Oncol. 2004; 94:818-820.
61. Sprogoe-Jakobsen S, Holund B. Immunohistochemistry (Ki-67 and p53) as a tool in determining malignancy in smooth muscle neoplasms (exemplified by a myxoid leiomyosarcoma of the uterus). APMIS. 1996;104:705-708.
62. Sreekantaiah C, Davis JR, Sandberg AA. Chromosomal abnormalities in leiomyosarcomas. Am J Pathol. 1993;142:293-305.
63. Sreenan JJ, Prayson RA, Biscotti CV, et al. Histopathologic findings in 107 uterine leiomyomas treated with leuprolide acetate compared with 126 controls. Am J Surg Pathol. 1996;20:427-432.
64. Tavassoli FA, Devilee P, eds. World Health Organization Classification of Tumours: Tumours of the Breast and Female Genital Organs. Lyon: International Agency for Research on Cancer Press; 2003: 236-239.
65. Taylor HB, Norris HJ. Mesenchymal tumors of the uterus. IV. Diagnosis and prognosis of leiomyosarcomas. Arch Pathol. 1966; 82:40-44.
66. Tiltman AJ. The effect of progestins on the mitotic activity of uterine fibromyomas. Int J Gynecol Pathol. 1985;4:89-96.
67. Vu K, Greenspan DL, Wu TC, et al. Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas. Hum Pathol. 1998;29:359-363.
68. Wauters CC, Ter Harmsel BW, Hermans MP, et al. Unexpected borderline malignant and malignant smooth muscle cell tumors of the uterine corpus in women treated with LH-RH analogues. Eur J Obstet Gynecol Reprod Biol. 1995;62:257-259.
69. Zaloudek CJ, Norris HJ, eds. Mesenchymal tumors of the uterus. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract. New York: Springer-Verlag; 1994.
70. Zhai YL, Kobayashi Y, Mori A, et al. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. Int J Gynecol Pathol. 1999;18:20-28.